Genetic testing company Invitae (NYSE: NVTA) has a lot of long-term potential as it could help improve the quality of healthcare for people and play a big role in transforming the industry. Below, I'll look at how much a $10,000 investment in the company would be worth today, and whether you should consider buying shares today. In 2018, Invitae was coming off a year where its revenue totaled $68 million and had more than doubled the prior-year's tally of $25 million.